Showing results (431-440 of 449) with videos related to
Sort By:
Pageof 45
Scientific Reports|August 6, 2021
Novel blood test for early biomarkers of preeclampsia and Alzheimer's diseaseShibin Cheng, Sayani Banerjee, Lori A Daiello, et al.Journal of the American College of Cardiology|May 9, 2020
Cognition After Lowering LDL-Cholesterol With EvolocumabBaris Gencer, François Mach, Jianping Guo, et al.Journal of Alzheimer'S Disease : JAD|November 25, 2017
Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's DiseaseCatherine M Roe, Ganesh M Babulal, Shruti Mishra, et al.Journal of the American Geriatrics Society|October 31, 2023
Changes in the burden of medications that may impair driving among older adults before and after a motor vehicle crashMelissa R Riester, Adam M D'Amico, Marzan A Khan, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Clinical ManifestationsJulia A Sinople, Em Teixeira, Charles Denby, et al.Alzheimer'S Research & Therapy|March 27, 2020
Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer's disease after a 27-month delay intervalJessica Alber, Paul Maruff, Cláudia Y Santos, et al.Journal of Applied Gerontology : the Official Journal of the Southern Gerontological Society|April 7, 2017
A Naturalistic Study of Driving Behavior in Older Adults and Preclinical Alzheimer Disease: A Pilot StudyGanesh M Babulal, Sarah H Stout, Tammie L S Benzinger, et al.JAMA Network Open|October 9, 2024
Medication Changes Among Older Drivers Involved in Motor Vehicle CrashesAndrew R Zullo, Melissa R Riester, Adam M D'Amico, et al.Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.NEJM Evidence|December 24, 2024
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with EvolocumabAndré Zimerman, Michelle L O'Donoghue, Xinhui Ran, et al.Pageof 45